Loading
Life sciences · Journal article
Pharmacia · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Tamoxifen remains a cornerstone in the treatment of estrogen receptor-positive breast cancer, yet its clinical performance is limited by poor aqueous solubility, high lipophilicity, and interindividual variability associated with CYP2D6-mediated formation of its more potent active metabolites. These challenges necessitate the development of advanced drug delivery systems. Nanotechnology-based formulations, particularly polymeric nanocarriers, have shown potential to improve solubility, pharmacokinetics, and therapeutic efficacy, although they do not inherently overcome CYP2D6-dependent metabolic variability. This review focuses on chitosan and its chemically modified derivatives as promising nanocarriers for tamoxifen delivery. Various modification strategies, including hydrophobic conjugation, graft copolymerization, and surface functionalization, are discussed in relation to encapsulation efficiency, release behavior, and biological performance. Reported studies demonstrate enhanced drug loading, sustained release, improved cellular uptake, and increased anticancer activity. Despite these advances, current research remains limited and lacks systematic comparisons. Further studies are required to optimize formulation design and support clinical translation of chitosan-based systems for tamoxifen therapy.